Evidence map›Paper›PMID 30655804›Full record

ArticleOncology letters2019

Carcinosarcoma of the esophagus: A report of 6 cases associated with zinc finger E-box-binding homeobox 1 expression.

Hiroki Harada, Kei Hosoda, Hiromitsu Moriya, Hiroaki Mieno, Akira Ema, Marie Washio, Mariko Kikuchi, Yoshimasa Kosaka, Masahiko Watanabe, Keishi Yamashita

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. EMT and cancer: what clinicians should know.Nature reviews. Clinical oncology · 2025
    Review
  4. Article
  5. Article
  6. Histopathological landscape of rare oesophageal neoplasms.World journal of gastroenterology · 2020
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hiroki HaradaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Kei HosodaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Hiromitsu MoriyaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Hiroaki MienoDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Akira EmaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Marie WashioDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Mariko KikuchiDepartment of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Yoshimasa KosakaDepartment of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Masahiko WatanabeDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Keishi YamashitaDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0375, Japan.
Kitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal carcinosarcoma (ECS) has been suggested to result from an epithelial mesenchymal transition (EMT) phenomenon. However, knowledge on its underlying molecular features is limited. The clinical and pathological features, and the prognosis of ECS require further investigation. In the present study, a total of 325 patients with esophageal tumors were observed between January 2004 and December 2014, of which 6 patients were diagnosed pathologically with ECS. The clinicopathological features were compared with those of corresponding cases with the identical pathological T stage (pT) of esophageal squamous cell carcinoma (ESCC). In terms of the clinical T stage (cT), the 6 cases were composed of cT1, cT2, cT3 and cT4 in 1, 1, 3 and 1 case, respectively. Nevertheless, pT was eventually diagnosed as pT1 in all cases. There was a large discrepancy between clinically diagnosed depth of tumor invasion prior to surgery and depth of tumor invasion following surgery. Zinc finger E-box-binding homeobox 1 (ZEB1), an EMT-associated transcription factor, was expressed only in the sarcoma component in all 6 cases of ECS. The ECS cases had a significantly poorer prognosis compared with the 115 pT1 ESCC cases. The present study suggests that the depth of invasion of ECS lesions does not correspond with their respective size, and the EMT of the carcinoma component may affect the prognosis by overexpression of the ZEB1 gene.

Indexed as

epithelial mesenchymal transitionesophageal carcinosarcomaesophageal squamous cell carcinomazinc finger E-box-binding homeobox 1 expression

Identifiers

PMID30655804
PMCPMC6313136
OpenAlexW2896866531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.